Celldex Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
6.86 |
3.57 |
2.63 |
39.02 |
276.31 |
721.18 |
| Przychód Δ r/r |
0.00% |
-47.93% |
-26.27% |
1380.84% |
608.12% |
161.00% |
| Przychód (min) |
5.70 |
2.39 |
1.35 |
39.02 |
141.72 |
369.88 |
| Przychód (max) |
8.36 |
5.31 |
4.81 |
39.02 |
504.55 |
1,316.89 |
| EBITDA (średnia) |
-6.86 |
-3.57 |
-2.63 |
-39.02 |
-276.31 |
-721.18 |
| EBIT (średnia) |
-6.86 |
-3.57 |
-2.63 |
-39.02 |
-276.31 |
-721.18 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-160.69 |
-222.19 |
-279.37 |
-300.32 |
-126.85 |
144.75 |
| Zysk netto % |
-2341.23% |
-6217.05% |
-10602.36% |
-769.66% |
-45.91% |
20.07% |
| EPS (średnia) |
-2.48 |
-3.45 |
-4.02 |
-3.87 |
-1.97 |
2.25 |
| Liczba analityków (Przychody) |
8 |
7 |
9 |
9 |
3 |
4 |
| Liczba analityków (EPS) |
8 |
8 |
9 |
7 |
5 |
2 |
| symbol |
CLDX |
CLDX |
CLDX |
CLDX |
CLDX |
CLDX |